251 related articles for article (PubMed ID: 28737129)
1. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
2. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
3. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
4. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
6.
Li YQ; Zhang XY; Chen J; Yin JY; Li XP
J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
[TBL] [Abstract][Full Text] [Related]
7. Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy.
Li YQ; Yin JY; Liu ZQ; Li XP
IUBMB Life; 2018 Mar; 70(3):183-191. PubMed ID: 29394468
[TBL] [Abstract][Full Text] [Related]
8. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.
Ip V; Liu JJ; Mercer JF; McKeage MJ
Mol Pain; 2010 Sep; 6():53. PubMed ID: 20836889
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
12. The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets.
Sun S; Cai J; Yang Q; Zhao S; Wang Z
Oncotarget; 2017 Feb; 8(9):16036-16051. PubMed ID: 27980217
[TBL] [Abstract][Full Text] [Related]
13. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
14. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
15. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
17. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
18. Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.
Matsumoto S; Tanaka T; Kurokawa H; Matsuno K; Hayashida Y; Takahashi T
Anticancer Res; 2007; 27(4B):2209-16. PubMed ID: 17695505
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
20. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]